<DOC>
	<DOCNO>NCT01424501</DOCNO>
	<brief_summary>This study ass safety immunogenicity GSK Biologicals ' investigational tuberculosis ( TB ) vaccine ( GSK 692342 ) compare placebo administer 0 , 1 month human immunodeficiency virus ( HIV ) negative adult receive treatment TB disease ( denote TB-treated cohort ) currently receive treatment TB disease ( denote TB-treatment cohort ) . For comparative purpose , subject never TB disease ( denote TB-naïve cohort ) also enrol .</brief_summary>
	<brief_title>Safety Immunogenicity Candidate Tuberculosis ( TB ) Vaccine Adults With TB Disease</brief_title>
	<detailed_description>A Protocol Amendment 1 , May 2012 , make follow decision add second country study ( i.e . Estonia ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female , include , 18 59 year age time first vaccination . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Seronegative HIV 1 2 antibody . No history current extrapulmonary tuberculosis TB . Additionally , base medical history , Subjects TBnaive cohort must active pulmonary disease indicate chest Xray . sign symptom TB . history chemoprophylaxis treatment TB . Subjects TBtreated cohort must history successful treatment pulmonary TB ( complete least 1 year prior vaccination ) . active pulmonary disease chest Xray . Subjects TBtreatment cohort must document treatment pulmonary TB ( smear culture confirm ) ongoing 24 month prior vaccination . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration register live vaccine foreseen study within 30 day precede first dose study vaccine administration register inactivated vaccine within 14 day precede first dose study vaccine . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any chronic drug therapy continue study period , opinion investigator could adversely interfere vaccine . History previous administration experimental TB vaccine . History previous exposure component investigational vaccine within 30 day precede first dose study vaccine . Administration immunoglobulins , immunotherapy and/or blood product within 3 month precede first dose study vaccination , plan administration study period . Planned participation participation another experimental protocol study period . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History chronic alcohol and/or drug abuse . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect . Pregnant female , lactate female female planning become pregnant discontinue contraceptive precaution active phase study ( study start till 2 month dose 2 ) . Additionally , TB naïve TB treat cohort : Acute chronic clinically relevant pulmonary , cardiovascular , hepatic renal function abnormality determine physical examination laboratory screen test Additionally , TB treatment cohort : Acute chronic clinically relevant pulmonary , cardiovascular , hepatic renal function abnormality determine physical examination laboratory screen test . Individuals grade 3 level exclude . Failure convert antiTB treatment end second month antiTB therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
	<keyword>HIV-negative</keyword>
	<keyword>tuberculosis treatment</keyword>
</DOC>